Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.9
USERS' SCORE
Good
Based on 3 Reviews
8.2
Supplement Facts
Serving Size: 2 Softgels
Serving Per Container: 60
Amount Per Serving
%DV
Calories
25
Total Fat
2.5 g
3%**
Total Fish Oil
2,600 mg
†
EPA (Eicosapentaenoic acid) Omega-3
750 mg
†
DHA (Docosahexaenoic acid) Omega-3
750 mg
†
DPA (Docosapentaenoic acid) Omega-3
150 mg
†
Top Medical Research Studies
9
We investigated how eicosapentaenoic acid (EPA) may help improve heart health after a heart attack. In our study, we induced myocardial infarction (MI) in male rats by ligating their coronary artery. Some of these rats received daily treatment with EPA, while others did not, allowing us to compare the effects.
Over 12 weeks, we observed that the rats treated with EPA showed better left ventricular function—essentially, their hearts were working more efficiently. Moreover, these rats had higher levels of EPA in their mitochondria, which are the energy factories of cells. Despite the damage caused by the heart attack, the EPA treatment helped maintain crucial energy levels and kept the mitochondrial function from declining, preserving a specific protein linked to cellular health.
Our findings suggest that including EPA in the diet can bolster mitochondrial quality and support heart function after an MI. This could mean that EPA may serve as an important dietary addition for promoting heart health following heart events.
Over 12 weeks, we observed that the rats treated with EPA showed better left ventricular function—essentially, their hearts were working more efficiently. Moreover, these rats had higher levels of EPA in their mitochondria, which are the energy factories of cells. Despite the damage caused by the heart attack, the EPA treatment helped maintain crucial energy levels and kept the mitochondrial function from declining, preserving a specific protein linked to cellular health.
Our findings suggest that including EPA in the diet can bolster mitochondrial quality and support heart function after an MI. This could mean that EPA may serve as an important dietary addition for promoting heart health following heart events.
Read More
9
DHA aids post-heart attack recovery
We explored the effects of docosahexaenoic acid (DHA) on heart attack recovery in rats. The study aimed to understand how DHA, alongside eicosapentaenoic acid (EPA), can influence heart failure following myocardial infarction (MI).
Using several groups of rats experiencing moderate heart issues, we evaluated how these omega-3 fatty acids impacted heart function. We found that both DHA and EPA effectively curtailed the hypertrophic response in heart cells. This response is a significant factor in heart failure, where heart tissue thickens and hardens.
Notably, both DHA and EPA inhibited the activity of a histone acetyltransferase called p300. This activity is linked to molecular changes that promote heart cell enlargement and fibrosis. In our analysis, we observed that these fatty acids not only preserved cardiac function but also prevented structural changes common after a heart attack.
Overall, we noted that DHA had a comparable protective effect to EPA, significantly improving heart health and reducing fibrosis in the heart tissue. As such, the findings suggest that incorporating DHA could be a heart-friendly choice post-heart attack.
Using several groups of rats experiencing moderate heart issues, we evaluated how these omega-3 fatty acids impacted heart function. We found that both DHA and EPA effectively curtailed the hypertrophic response in heart cells. This response is a significant factor in heart failure, where heart tissue thickens and hardens.
Notably, both DHA and EPA inhibited the activity of a histone acetyltransferase called p300. This activity is linked to molecular changes that promote heart cell enlargement and fibrosis. In our analysis, we observed that these fatty acids not only preserved cardiac function but also prevented structural changes common after a heart attack.
Overall, we noted that DHA had a comparable protective effect to EPA, significantly improving heart health and reducing fibrosis in the heart tissue. As such, the findings suggest that incorporating DHA could be a heart-friendly choice post-heart attack.
Read More
9
We explored the effects of specialized proresolving mediators derived from docosapentaenoic acid, particularly resolvins (RvD), on heart attack risk. Through our study, we found that the levels of these mediators in the bloodstream display a daily, or diurnal, rhythm in healthy individuals.
However, in patients who are at risk of heart attacks, the production of RvDs is significantly impaired. This decrease in RvD correlates with heightened activation of blood cells, such as platelets and leukocytes, which could contribute to inflammation and cardiovascular issues.
Importantly, when we administered RvD to both healthy volunteers and those with cardiovascular conditions, we noted a considerable reduction in the activation of these blood components. In experiments with mice predisposed to cardiovascular disease, treatment with RvD5 also resulted in less clustering of platelets and leukocytes, and a reduction in markers associated with arterial damage.
These findings suggest that maintaining optimal levels of docosapentaenoic acid and its derived mediators might be crucial for preventing heart-related issues, particularly by controlling inflammation and blood cell activity.
However, in patients who are at risk of heart attacks, the production of RvDs is significantly impaired. This decrease in RvD correlates with heightened activation of blood cells, such as platelets and leukocytes, which could contribute to inflammation and cardiovascular issues.
Importantly, when we administered RvD to both healthy volunteers and those with cardiovascular conditions, we noted a considerable reduction in the activation of these blood components. In experiments with mice predisposed to cardiovascular disease, treatment with RvD5 also resulted in less clustering of platelets and leukocytes, and a reduction in markers associated with arterial damage.
These findings suggest that maintaining optimal levels of docosapentaenoic acid and its derived mediators might be crucial for preventing heart-related issues, particularly by controlling inflammation and blood cell activity.
Read More
Most Useful Reviews
8.5
Health improvement noted
1 people found this helpful
I feel so much better! After having a heart attack and receiving five stents, my son recommended this fish oil. I take them daily, and my health has significantly improved. I would recommend them even to healthy individuals like my son.
Read More
6
Heart health benefits
The quality and size are good, with benefits for heart health, improving good cholesterol and preventing harmful cholesterol.
Read More
7.5
Supports athletes' performance
Excellent for athletes and those with heart problems, I take half the dose and notice its support for my physical ability. It has really helped me manage my cardiovascular health and reduce the risk of heart attack.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.9
- All Researches
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
Read More
9
We explored the role of eicosapentaenoic acid (EPA) in heart attack recovery, particularly its effect on restoring blood flow during ST-elevation myocardial infarction (STEMI). Our focus was on understanding whether higher levels of EPA relative to arachidonic acid could lead to faster recovery and better outcomes for patients experiencing this type of heart attack.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
Read More
9
We explored how eicosapentaenoic acid (EPA) and its metabolites can protect heart cells during a heart attack, specifically focusing on a laboratory model for ischemic injury. Our investigation centered on a specific receptor found in heart cells, known as the Free Fatty Acid Receptor 4 (Ffar4).
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
Read More
9
Significant heart attack risk reduction
In this extensive study involving nearly 5,800 patients with atherosclerotic cardiovascular disease (ASCVD) and high triglyceride levels, we explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing the risk of major adverse cardiovascular events (MACE) like heart attacks.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Read More
9
We explored the cardiovascular benefits of eicosapentaenoic acid, specifically through a substance called icosapent ethyl (IPE), in individuals with elevated levels of lipoprotein(a). This post hoc analysis took place in a study called REDUCE-IT, which involved over 8,000 participants who were either battling established cardiovascular disease or were at high risk due to diabetes and other factors.
Participants in the study were given either IPE or a placebo while maintaining their statin therapy. We observed that elevated lipoprotein(a) concentrations were linked to an increased risk of major adverse cardiovascular events, even when low-density lipoprotein cholesterol was managed well.
Importantly, IPE demonstrated a consistent ability to lower the risk of these heart issues among participants, regardless of their lipoprotein(a) levels. This effect was particularly noticeable for those with elevated lipoprotein(a), showing that IPE could be beneficial in managing cardiovascular risk in this group.
Overall, the findings highlight the potential of eicosapentaenoic acid as a valuable treatment option for reducing heart attack risk in high-risk patients, emphasizing its importance alongside traditional therapies.
Participants in the study were given either IPE or a placebo while maintaining their statin therapy. We observed that elevated lipoprotein(a) concentrations were linked to an increased risk of major adverse cardiovascular events, even when low-density lipoprotein cholesterol was managed well.
Importantly, IPE demonstrated a consistent ability to lower the risk of these heart issues among participants, regardless of their lipoprotein(a) levels. This effect was particularly noticeable for those with elevated lipoprotein(a), showing that IPE could be beneficial in managing cardiovascular risk in this group.
Overall, the findings highlight the potential of eicosapentaenoic acid as a valuable treatment option for reducing heart attack risk in high-risk patients, emphasizing its importance alongside traditional therapies.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
8.5
Health improvement noted
1 people found this helpful
I feel so much better! After having a heart attack and receiving five stents, my son recommended this fish oil. I take them daily, and my health has significantly improved. I would recommend them even to healthy individuals like my son.
Read More
6
Heart health benefits
The quality and size are good, with benefits for heart health, improving good cholesterol and preventing harmful cholesterol.
Read More
7.5
Supports athletes' performance
Excellent for athletes and those with heart problems, I take half the dose and notice its support for my physical ability. It has really helped me manage my cardiovascular health and reduce the risk of heart attack.
Read More
Frequently Asked Questions
7.5
Supports athletes' performance
Excellent for athletes and those with heart problems, I take half the dose and notice its support for my physical ability. It has really helped me manage my cardiovascular health and reduce the risk of heart attack.
6
Heart health benefits
The quality and size are good, with benefits for heart health, improving good cholesterol and preventing harmful cholesterol.
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
8
We explored the impact of eicosapentaenoic acid (EPA) on heart attacks and other cardiovascular events through a comprehensive analysis of multiple clinical trials. Our study included data from 18 randomized controlled trials that involved over 134,000 participants. These individuals were either given EPA alone, a combination of EPA and DHA (docosahexaenoic acid), or a control substance.
Our findings indicate that omega-3 fatty acid supplementation, specifically EPA, significantly reduced the risk of coronary revascularization and heart attacks. We observed that participants who received EPA experienced a 10% lower risk of undergoing coronary revascularization procedures, and a 11% lower risk of having a heart attack compared to those in the control group.
Interestingly, when we compared EPA alone to the combination therapy of DHA and EPA, we found that EPA provided even more substantial benefits in reducing the need for revascularization procedures. This suggests that EPA may play a crucial role in enhancing cardiovascular health, making it a valuable option for patients, particularly those already on statin therapy.
Overall, our exploration indicates that EPA holds promise in diminishing heart attack risks and improving cardiovascular outcomes. However, further research is needed to fully understand the mechanisms at play and the specific benefits of EPA in different prevention scenarios.
Our findings indicate that omega-3 fatty acid supplementation, specifically EPA, significantly reduced the risk of coronary revascularization and heart attacks. We observed that participants who received EPA experienced a 10% lower risk of undergoing coronary revascularization procedures, and a 11% lower risk of having a heart attack compared to those in the control group.
Interestingly, when we compared EPA alone to the combination therapy of DHA and EPA, we found that EPA provided even more substantial benefits in reducing the need for revascularization procedures. This suggests that EPA may play a crucial role in enhancing cardiovascular health, making it a valuable option for patients, particularly those already on statin therapy.
Overall, our exploration indicates that EPA holds promise in diminishing heart attack risks and improving cardiovascular outcomes. However, further research is needed to fully understand the mechanisms at play and the specific benefits of EPA in different prevention scenarios.
9
Significant heart attack risk reduction
In this extensive study involving nearly 5,800 patients with atherosclerotic cardiovascular disease (ASCVD) and high triglyceride levels, we explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing the risk of major adverse cardiovascular events (MACE) like heart attacks.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
7
Eicosapentaenoic acid shows uncertain benefits
We conducted a thorough evaluation of how eicosapentaenoic acid (EPA) affects the risk of heart attacks in patients with coronary artery disease. Our study involved a well-structured design, where patients were randomly assigned to receive either icosapent ethyl, a form of EPA, or a control treatment. The focus was on those with low levels of EPA relative to arachidonic acid (AA), specifically looking to see if this treatment provided heart health benefits.
We analyzed data from almost 4,000 patients over a median period of five years. The results showed a lower percentage of major cardiovascular events, like heart attacks, in those treated with EPA compared to the control group. However, despite the numerically favorable outcomes, the differences did not reach statistical significance—suggesting that while there may be benefits, they are not definitively proven. Additionally, the rates of adverse effects, including new-onset atrial fibrillation, were noted, emphasizing the importance of monitoring patients even with the potential benefits of EPA therapy.
Overall, while we observed some positive trends in cardiovascular outcomes with eicosapentaenoic acid treatment, the findings indicate that there is not enough evidence to conclusively affirm its efficacy in preventing heart attacks among patients already receiving statin treatment.
We analyzed data from almost 4,000 patients over a median period of five years. The results showed a lower percentage of major cardiovascular events, like heart attacks, in those treated with EPA compared to the control group. However, despite the numerically favorable outcomes, the differences did not reach statistical significance—suggesting that while there may be benefits, they are not definitively proven. Additionally, the rates of adverse effects, including new-onset atrial fibrillation, were noted, emphasizing the importance of monitoring patients even with the potential benefits of EPA therapy.
Overall, while we observed some positive trends in cardiovascular outcomes with eicosapentaenoic acid treatment, the findings indicate that there is not enough evidence to conclusively affirm its efficacy in preventing heart attacks among patients already receiving statin treatment.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Yamada R, Uematsu M, Nakamura T, Kobayashi T, Horikoshi T, et al. Elevated eicosapentaenoic acid to arachidonic acid ratio and rapid coronary blood flow restoration in ST-elevation myocardial infarction. Hellenic J Cardiol. 2025. 10.1016/j.hjc.2025.01.003
- Puccini SJ, Healy CL, Harsch BA, Ahmed AR, Shearer GC, et al. A Cell Autonomous Free fatty acid receptor 4 - ChemR23 Signaling Cascade Protects Cardiac Myocytes from Ischemic Injury. bioRxiv. 2025. 10.1101/2024.11.26.625260
- Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. 10.1161/CIRCULATIONAHA.123.065520
- Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. 10.1093/eurjpc/zwae184
- Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, et al. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. Eur Heart J Cardiovasc Pharmacother. 2024;10:488. 10.1093/ehjcvp/pvae030
- Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024;83:1529. 10.1016/j.jacc.2024.02.016
- Sabbour H, Bhatt DL, Elhenawi Y, Aljaberi A, Bennani L, et al. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovasc Drugs Ther. 2024. 10.1007/s10557-023-07519-z
- Bernhard B, Heydari B, Abdullah S, Francis SA, Lumish H, et al. Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial. Int J Cardiol. 2024;399:131698. 10.1016/j.ijcard.2023.131698
- Le VT, Knight S, Watrous JD, Najhawan M, Dao K, et al. Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Front Cardiovasc Med. 2023;10:1229130. 10.3389/fcvm.2023.1229130
- Myhre PL, Berge T, Kalstad AA, Tveit SH, Laake K, et al. Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial. Clin Nutr. 2023;42:1657. 10.1016/j.clnu.2023.07.002
- Borghi C, Bragagni A. Clinical results and mechanism of action of icosapent ethyl. Eur Heart J Suppl. 2023;25:B37. 10.1093/eurheartjsupp/suad088
- Chiusolo S, Bork CS, Gentile F, Lundbye-Christensen S, Harris WS, et al. Adipose tissue n-3/n-6 fatty acids ratios versus n-3 fatty acids fractions as predictors of myocardial infarction. Am Heart J. 2023;262:38. 10.1016/j.ahj.2023.03.019
- Rabbat MG, Lakshmanan S, Benjamin MM, Doros G, Kinninger A, et al. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Heart J Cardiovasc Imaging. 2023;24:866. 10.1093/ehjci/jead063
- Kobara M, Shiraishi T, Noda K, Toba H, Nakata T. Eicosapentaenoic Acid Preserves Mitochondrial Quality and Attenuates Cardiac Remodeling After Myocardial Infarction in Rats. J Cardiovasc Transl Res. 2023;16:816. 10.1007/s12265-023-10363-z
- Luo X, Liu M, Wang S, Chen Y, Bao X, et al. Combining metabolomics and OCT to reveal plasma metabolic profiling and biomarkers of plaque erosion and plaque rupture in STEMI patients. Int J Cardiol. 2023;390:131223. 10.1016/j.ijcard.2023.131223
- Bork CS, Lundbye-Christensen S, Venø SK, Lasota AN, Tjønneland A, et al. Intake of marine and plant-derived n-3 fatty acids and development of atherosclerotic cardiovascular disease in the Danish Diet, Cancer and Health cohort. Eur J Nutr. 2023;62:1389. 10.1007/s00394-022-03081-w
- Park GH, Cho JH, Lee D, Kim Y. Association between Seafood Intake and Cardiovascular Disease in South Korean Adults: A Community-Based Prospective Cohort Study. Nutrients. 2022;14. 10.3390/nu14224864
- Bassuk SS, Manson JE. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence. Cardiovasc Res. 2023;119:1297. 10.1093/cvr/cvac172
- Alfaddagh A, Kapoor K, Dardari ZA, Bhatt DL, Budoff MJ, et al. Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis. 2022;353:11. 10.1016/j.atherosclerosis.2022.06.1018
- Sunagawa Y, Katayama A, Funamoto M, Shimizu K, Shimizu S, et al. The polyunsaturated fatty acids, EPA and DHA, ameliorate myocardial infarction-induced heart failure by inhibiting p300-HAT activity in rats. J Nutr Biochem. 2022;106:109031. 10.1016/j.jnutbio.2022.109031
- Halade GV, Kain V, De La Rosa X, Lindsey ML. Metabolic transformation of fat in obesity determines the inflammation resolving capacity of splenocardiac and cardiorenal networks in heart failure. Am J Physiol Heart Circ Physiol. 2022;322:H953. 10.1152/ajpheart.00684.2021
- Shi Y, Li H, Wu T, Wang Q, Zhu Q, et al. Docosahexaenoic Acid-Enhanced Autophagic Flux Improves Cardiac Dysfunction after Myocardial Infarction by Targeting the AMPK/mTOR Signaling Pathway. Oxid Med Cell Longev. 2022;2022:1509421. 10.1155/2022/1509421
- Wang CP, Lee CC, Wu DY, Chen SY, Lee TM. Differential effects of EPA and DHA on PPARγ-mediated sympathetic innervation in infarcted rat hearts by GPR120-dependent and -independent mechanisms. J Nutr Biochem. 2022;103:108950. 10.1016/j.jnutbio.2022.108950
- Myhre PL, Kalstad AA, Tveit SH, Laake K, Schmidt EB, et al. Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial. J Intern Med. 2022;291:637. 10.1111/joim.13442
- Pertiwi K, Küpers LK, de Goede J, Zock PL, Kromhout D, et al. Dietary and Circulating Long-Chain Omega-3 Polyunsaturated Fatty Acids and Mortality Risk After Myocardial Infarction: A Long-Term Follow-Up of the Alpha Omega Cohort. J Am Heart Assoc. 2021;10:e022617. 10.1161/JAHA.121.022617
- Xuan C, Tian QW, Li H, Guo JJ, He GW, et al. Serum fatty acids profile and association with early-onset coronary artery disease. Ther Adv Chronic Dis. 2021;12:20406223211033102. 10.1177/20406223211033102
- Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, et al. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. J Am Heart Assoc. 2021;10:e017401. 10.1161/JAHA.120.017401
- Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, et al. Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction. EBioMedicine. 2019;46:264. 10.1016/j.ebiom.2019.07.024
- Desnoyers M, Gilbert K, Madingou N, Gagné MA, Daneault C, et al. A high omega-3 fatty acid diet rapidly changes the lipid composition of cardiac tissue and results in cardioprotection. Can J Physiol Pharmacol. 2018;96:916. 10.1139/cjpp-2018-0043
- Colas RA, Souza PR, Walker ME, Burton M, Zasłona Z, et al. Impaired Production and Diurnal Regulation of Vascular RvD Increase Systemic Inflammation and Cardiovascular Disease. Circ Res. 2018;122:855. 10.1161/CIRCRESAHA.117.312472
- Harris WS, Kennedy KF, O'Keefe JH, Spertus JA. Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction. Int J Cardiol. 2013;168:53. 10.1016/j.ijcard.2012.09.076
- Smith PJ, Blumenthal JA, Babyak MA, Georgiades A, Sherwood A, et al. Association between n-3 fatty acid consumption and ventricular ectopy after myocardial infarction. Am J Clin Nutr. 2009;89:1315. 10.3945/ajcn.2008.26829
- Sun Q, Ma J, Campos H, Rexrode KM, Albert CM, et al. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am J Clin Nutr. 2008;88:216.
- Oda E, Hatada K, Katoh K, Kodama M, Nakamura Y, et al. A case-control pilot study on n-3 polyunsaturated fatty acid as a negative risk factor for myocardial infarction. Int Heart J. 2005;46:583.
- Simon JA, Hodgkins ML, Browner WS, Neuhaus JM, Bernert JT, et al. Serum fatty acids and the risk of coronary heart disease. Am J Epidemiol. 1995;142:469.
- Santos MJ, López-Jurado M, Llopis J, Urbano G, Mataix FJ. Influence of dietary supplementation with fish on plasma fatty acid composition in coronary heart disease patients. Ann Nutr Metab. 1995;39:52.
